Abstract
Zijun Yidan Xu-Monette, 吴得红, Michael Boe Møller, Carlo Visco, Eric D. Hsi, Xiaoxian Zhao, Beibei Lv, Bangchen Wang, Xin Cao, April Chiu, Karen Dybkær, Govind Bhagat, Youli Zu, Santiago Montes‐Moreno, Zenggang Pan, Leon Bernal‐Mizrachi, J. Han van Krieken, William W.L. Choi, Wayne Tam, Andrés J.M. Ferreri, Benjamin Marshall Parsons, Farzaneh Khajouei, Kristin L Sikkink, Alex R. Hastie, Anthony D. Schmitt, Ken H. Young
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Diffuse large B-cell lymphoma
10.1056/nejmra2027612 · 2021
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
10.1038/s41375-022-01620-2 · 2022
Large B-cell lymphomas in the 5th edition of the WHO-classification of haematolymphoid neoplasms-updated classification and new concepts
10.3390/cancers15082285 · 2023
The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH
10.1182/blood.2019002600 · 2019
Unbalanced MYC break-apart FISH patterns indicate the presence of a MYC rearrangement in HGBCL-DH-BCL2
10.1182/blood.2024025603 · 2024
RNAseq analysis for accurate identification of fusion partners in tumor specific translocations detected by standard FISH probes in hematologic malignancies
10.1177/2632010x241230262 · 2024
Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential
10.1038/s41375-023-02134-1 · 2024
Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium
10.1200/jco.19.00743 · 2019
MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study
10.1182/blood-2015-05-647602 · 2015
High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology
10.1182/bloodadvances.2018023572 · 2018
Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements
10.3324/haematol.2018.190157 · 2018
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes
10.1038/s41408-024-01148-x · 2024
Next-generation sequencing in diffuse large B-cell lymphoma highlights molecular divergence and therapeutic opportunities: a LYSA study
10.1158/1078-0432.ccr-15-2305 · 2016
LYmphoid NeXt-Generation Sequencing (LYNX) Panel: a comprehensive capture-based sequencing tool for the analysis of prognostic and predictive markers in lymphoid malignancies
10.1016/j.jmoldx.2021.05.007 · 2021
Integrated genomic DNA/RNA profiling vs fluorescence in situ hybridization in the detection of MYC and BCL2 (and BCL6) rearrangements in La-ge B-cell lymphomas: updates amid the new WHO classification of lymphoid neoplasms
10.1093/ajcp/aqad006 · 2023
Comparison between integrated genomic DNA/RNA profiling and fluorescence in situ hybridization in the detection of MYC, BCL-2, and BCL-6 gene rearrangements in large B-cell lymphomas
10.1093/ajcp/aqz172 · 2020
Detection of gene fusions and rearrangements in formalin-fixed, paraffin-embedded solid tumor specimens using high-throughput chromosome conformation capture
10.1016/j.jmoldx.2025.01.007 · 2025
Large B-cell lymphoma with mystery rearrangement: applying Hi-C to the detection of clinically relevant structural abnormalities
10.1111/bjh.19611 · 2024
Evaluation of Hi-C sequencing for detection of gene fusions in hematologic and solid tumor pediatric cancer samples
10.3390/cancers16172936 · 2024
Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies
10.1016/j.xgen.2026.101166 · 2025
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
10.1038/modpathol.2013.214 · 2014
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
10.3324/haematol.2012.066209 · 2013
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
10.1182/blood-2012-10-460063 · 2013
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL
10.1158/2326-6066.cir-18-0439 · 2019
Tumor-infiltrating normal B cells revealed by immunoglobulin repertoire clonotype analysis are highly prognostic and crucial for antitumor immune responses in DLBCL
10.1158/1078-0432.ccr-23-1554 · 2023
Arima SV Pipeline for Mapping, SV Detection and QC
2025
HiCUP: pipeline for mapping and processing Hi-C data
10.12688/f1000research.7334.1 · 2015
Integrative detection and analysis of structural variation in cancer genomes
10.1038/s41588-018-0195-8 · 2018
Juicer provides a one-click system for analyzing loop-resolution Hi-C experiments
10.1016/j.cels.2016.07.002 · 2016
Juicebox provides a visualization system for Hi-C contact maps with unlimited zoom
10.1016/j.cels.2015.07.012 · 2016
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
10.1038/leu.2012.83 · 2012
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
10.1002/cncr.28664 · 2014
Genetics of diffuse large B-cell lymphoma
10.1182/blood-2017-11-764332 · 2018
Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies
10.1186/s40425-019-0730-x · 2019
Clinical and biologic significance of MYC genetic mutations in de novo diffuse large B-cell lymphoma
10.1158/1078-0432.ccr-15-2296 · 2016
The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee
10.1182/blood.2022015851 · 2022
A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas
10.1038/s41375-022-01764-1 · 2023
Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma
10.1182/blood-2016-05-715094 · 2016
B-cell receptor silencing reveals the origin and dependencies of high-grade B-cell lymphomas with MYC and BCL2 rearrangements
10.1158/2643-3230.bcd-25-0099 · 2025
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)
10.1182/blood.2024024251 · 2024
Prognostic gene expression and microRNA profiling signatures and genetic alterations in primary testicular diffuse large B-cell lymphoma
10.1038/s41408-025-01323-8 · doi-reference
ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer
10.1126/sciadv.adg2263 · doi-reference
A small-molecule inhibitor of BCL10-MALT1 interaction abrogates progression of diffuse large B cell lymphoma
10.1172/jci164573 · doi-reference
Programmed death ligand 1 (PD-L1) expression in lymphomas: state of the art
10.3390/ijms25126447 · doi-reference
MYC status determination in aggressive B-cell lymphoma: the impact of FISH probe selection
10.1111/his.12178 · doi-reference
Proinflammatory GSDMD activation in live macrophages and DLBCL cells marks cognate interactions and better prognosis
10.1182/bloodadvances.2025017643 · doi-reference
PD-1 expression and clinical PD-1 blockade in B-cell lymphomas
10.1182/blood-2017-07-740993 · doi-reference
Targetable genetic features of primary testicular and primary central nervous system lymphomas
10.1182/blood-2015-10-673236 · doi-reference
Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma
10.1182/blood-2013-10-535443 · doi-reference
Large B-cell lymphoma with IRF4 gene rearrangements: differences in clinicopathologic, immunophenotypic and cytogenetic features between pediatric and adult patients
10.1016/j.humpath.2022.10.011 · doi-reference
Reclassification of diffuse large B cell lymphoma to large B cell lymphoma with IRF4 rearrangement in an adult population
10.1111/his.14885 · doi-reference
Distinct molecular profile of IRF4-rearranged large B-cell lymphoma
10.1182/blood.2019002699 · doi-reference
A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL
10.1182/bloodadvances.2020001949 · doi-reference
DLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphoma
10.1182/blood.2024025652 · doi-reference
Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries
10.18632/oncotarget.3479 · doi-reference
Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma
10.1158/1078-0432.ccr-21-2949 · doi-reference
Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma
10.1038/s41408-024-01146-z · doi-reference
Cyclin D1 rearranged diffuse large B-cell lymphoma-an evolving concept
10.1038/s41375-025-02794-1 · doi-reference
Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy
10.1200/jco.18.01314 · doi-reference
Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma
10.1200/jco.18.01583 · doi-reference